Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) COO Robert J. Perez sold 1,518 shares of the stock on the open market in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $67.50, for a total value of $102,465.00. Following the transaction, the chief operating officer now directly owns 45,869 shares in the company, valued at approximately $3,096,158. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on CBST shares. Analysts at Ned Davis Research upgraded shares of Cubist Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Friday, April 25th. They now have a $70.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Cubist Pharmaceuticals from $80.00 to $90.00 in a research note on Monday, April 21st. They now have an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $75.07.

Cubist Pharmaceuticals (NASDAQ:CBST) traded down 4.21% during mid-day trading on Thursday, hitting $66.41. 950,887 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 52 week low of $47.14 and a 52 week high of $82.12. The stock has a 50-day moving average of $68.30 and a 200-day moving average of $69.84. The company’s market cap is $5.001 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Tuesday, April 22nd. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.